Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast citing strong sales of its newer immunology drugs Skyrizi and Rinvoq.

AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic API production in the ...

Over the past five years, ABBV has experienced a negative one-day return following its earnings announcements in 65% of ...

AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $212.70 today based on a price of $204.94 for ABBV at the time of writing.

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study to ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Study Overview: AbbVie is conducting a Phase 2/3 ...